business unit manager
ATOS
Total years of experience :23 years, 5 Months
Atos pharma
From
December 2019
My Responsibility:
Data Analysis, Interpretation, and Communication: I was able to analyze the data generated from IMS & CLM to identify the key market opportunities
Performance and Program Metrics: I measures and evaluates the impact of our key activities and programs.
Forecasting : initiate our long term sales revenue and develop the relevant strategy and tactics for upcoming 5-10 years
Challenging: Our sales team by setting their sales and expense budget and discuss our brand strategies and Tactics
Endorsement: of the whole stakeholder to ensure our high performance and develop our product mix, and Average sales price with our key account customers
Marketing Execution :And the ability to create and shift the gear to achieve our corporate goals
for the Gento -urinary business units
Egypt (Ant infective and Prolactin inhibitor)
HISTORY OF ACCOMPLISHMENTS TASK
I was recognized as best PSR in Pharmacia in terms of Performance and sales then I was promoted as Senior Product specialists in Cardiovascular and total parental nutrition in 1993
In 1996, I was promoted as a Product Manager for ophthalmology and endocrinology
In 1997, I was able to launch Genotropine for endocrinologists and to make Genotropine as the drug of choice for short stature chidren and to secure its leading position among growth hormone deficiency segment in Saudi arabia and the Gulf markets.
In 1998, I was selected to conduct a clinical trial for Detrusitol as a prelaunch activity in three big accounts and the numbers of patients included were 60 patients and the impact of this trial was highly relevant on Detrusitol registration
In 2002, I was able to launch Xalatan as an innovative treatment in Glaucoma treatment in Saudi Arabia and United Arab of Emirate, I was be to get Number 1 rank (IMS DATA, 2002) within two years after the Launch.
In 2003, I was promoted as a group product manager for Egypt and I was responsible for ophthalmology, endocrinology and critical care in AFME and to generate almost 43 M$ from these therapy area.
In 2009, I was assigned as senior product manager for Anti- infective and Prolactin inhibitor in Egypt and I was able achieve 96 MLE with 16% growth (Unasyn 12% growth, Dostinex 41% growth and Diflucan 16% growth)
In 2011, I was assigned as Marketing manager and I was able to achieve with the GU team 89 MLE ( with 30% growth in Dostinex and 9% growth in Diflucan)
In 2012, The GU Team achieve 119 MLE with 33% growth over last year ( Unasyn oral 42% growth, Unasyn injection 37% growth, Dostinex 21% growth, and Diflucan 27% growth)
In 2013, I moved to the outsourced team and we succeed to achieve 63.5 M LE and these sales revenue were driven by Feldene flash 21% growth, Ponstan 25% growth and Debridat 21% growth as we were able to build up the team and effectively manage their Target, Training, development, mentor their IDP and finally assess their performance
In 2014, the outsourcing products achieve 55 MLE with 11% growth ( Feldene amp. achieve 14 MLE with 9% while Feldene oral achieve 15 MLE with 7% growth) and we were able to switch Multi pharm outsourced products to UCP without compromising the sales revenue.
In 2015, I work closely with Pfizer and UCP management to deliver the challenging financial outcomes that are needed to achieve Pfizer and UCP sales Objectives and to achieve 60 MLE (YTD P10, 2015 sales 46.5 MLE that 99% Vs target with 9% growth)
In 2017, I get new responsibility as marketing manager to lead Pfizer Anti -infective that represent 758 MLE sales revenue with 58% share and my team composed of three Product Manager responsible for Pfizer Anti-bacterial and Anti-Fungal portfolio
In 2017, I shared in the Portfolio optimization project that has the responsibility to assign the new team structure (Hospital and Private ) and the portfolio under their responsibility
In 2017, I was a member of the CM forum that will conduct the path forward project (Restore 80% of Pfizer revenue with 50% of the field force)
In 2018 we Successfully conduct the critical care Summit, I care summit and 57357 preceptorship Symposium with almost 180 oncologists from AfMEA region
In 2018, we were able to Launch Meronem and Precedex in Egypt
In 2018 Pfizer Egypt Anti-infective was selected among the top 20 top performer markets worldwide as we were able to be ranked as No1 Anti-infective company among the Egyptians Pharmaceutical companies in Hospital sector
(Ophthalmic, endocrinology and critical care)
Product Champion MENeA
Endocrinology and ophthalmology
Strategic business planning 1st part (London 1996)
Strategic business planning 2nd part (Paris 1997)
Clinical research associate program (Italy1997)
Strategic operating procedure ( Italy1997)
Pharmacia Marketing model program ( Barcelona 2001)
Strategic brand management (Milan 2001)
Best managed Behavior &Leadership skills (Dubai 2002)
Advanced product manager development (Paris, 2005)
Strategic planning, market analysis, forecasting and advertising (livon, Cairo, 2006)
Strategic thinking (Cairo, 2008)
in
in